IND-enabling safety tox studies for FDA submission in just 9 months

Learn how Syngene supported a pharma company in completing IND-enabling safety tox studies for their lead compound for treating painful neuropathies in less than nine months.

Author

Latest Blogs

Self-amplifying RNA vaccine vials and syringe representing mRNA-based therapeutics

Self-amplifying RNA: the next chapter in mRNA therapeutics

Laboratory glassware with green leaves illustrating green chemistry in pharmaceuticals.

Green chemistry principles for a sustainable future in pharma

Integrated drug discovery scientist analysing digital lab data

Integrated Drug Discovery: why expertise matters

Bispecific antibodies: engineering complexity into simplicity

3D molecular model showing protein-protein interaction with two large structures in brown and blue, and a smaller pink molecule bound to the blue region.

Integrated Expertise for Complex Modalities: Driving Innovation in Molecular Glue Discovery

Scientists analysing samples for AAV gene therapy in a modern lab

Plasmid, mRNA, & Viral Vector Manufacturing: Scaling for the Gene Therapy Boom

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details